Sistema de Salut de Catalunya
Institut Català de la Salut
[Netchine I] Sorbonne Université, INSERM, UMR_S938 Centre de Recherche Saint Antoine, APHP, Hôpital Armand Trousseau, Explorations Fonctionnelles Endocriniennes, Paris, France. [van der Steen M] Department of Paediatrics, Subdivision of Endocrinology, Erasmus University Medical Centre, Rotterdam, Netherlands. [López-Bermejo A] Institut d’Investigació Biomèdica de Girona (IDIBGI), Salt, Spain. Hospital Universitari de Girona Dr. Josep Trueta, Institut Català de la Salut (ICS), Girona, Spain. [Koledova E] Global Medical Affairs Department, Merck KGaA, Darmstadt, Germany. [Maghnie M] Department of Pediatrics, Institute for Research, Hospitalization and Health Care (IRCCS) Children's Hospital Giannina Gaslini, Genova, Italy. Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal, and Child Health, University of Genova, Genova, Italy
Hospital Universitari de Girona Dr Josep Trueta
2022-01-24T13:12:34Z
2022-01-24T13:12:34Z
2021-05-13
Hormona del creixement; Metabolisme; Síndrome de Russell-Silver
Hormona del crecimiento; Metabolismo; Síndrome de Russell-Silver
Growth hormone; Metabolism; Russell–Silver syndrome
Children born small for gestational age (SGA) comprise a heterogeneous group due to the varied nature of the cause. Approximately 85-90% have catch-up growth within the first 4 postnatal years, while the remainder remain short. In later life, children born SGA have an increased risk to develop metabolic abnormalities, including visceral adiposity, insulin resistance, and cardiovascular problems, and may have impaired pubertal onset and growth. The third "360° European Meeting on Growth and Endocrine Disorders" in Rome, Italy, in February 2018, funded by Merck KGaA, Germany, included a session that examined aspects of short children born SGA, with three presentations followed by a discussion period, on which this report is based. Children born SGA who remain short are eligible for GH treatment, which is an approved indication. GH treatment increases linear growth and can also improve some metabolic abnormalities. After stopping GH at near-adult height, metabolic parameters normalize, but pharmacological effects on lean body mass and fat mass are lost; continued monitoring of body composition and metabolic changes may be necessary. Guidelines have been published on diagnosis and management of children with Silver-Russell syndrome, who comprise a specific group of those born SGA; these children rarely have catch-up growth and GH treatment initiation as early as possible is recommended. Early and moderate pubertal growth spurt can occur in children born SGA, including those with Silver-Russell syndrome, and reduce adult height. Treatments that delay puberty, specifically metformin and gonadotropin releasing hormone analogs in combination with GH, have been proposed, but are used off-label, currently lack replication of data, and require further studies of efficacy and safety.
The third 360° European Meeting on Growth and Endocrine Disorders was funded by Merck KGaA, Germany.
Article
Published version
English
Somatotropina; Estatura baixa; Metabolisme - Trastorns; CHEMICALS AND DRUGS::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones::Peptide Hormones::Pituitary Hormones::Pituitary Hormones, Anterior::Growth Hormone; DISEASES::Nutritional and Metabolic Diseases::Metabolic Diseases; NAMED GROUPS::Persons::Age Groups::Child; COMPUESTOS QUÍMICOS Y DROGAS::hormonas, sustitutos de hormonas y antagonistas de hormonas::hormonas::hormonas peptídicas::hormonas hipofisarias::hormonas adenohipofisarias::hormona del crecimiento; ENFERMEDADES::enfermedades nutricionales y metabólicas::enfermedades metabólicas; DENOMINACIONES DE GRUPOS::personas::Grupos de Edad::niño
Frontiers Media
Frontiers in Pediatrics;9
https://doi.org/10.3389/fped.2021.655931
Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/
